Burns - Pipeline Review, H2 2019

Publisher Name :
Date: 25-Nov-2019
No. of pages: 99
Inquire Before Buying

Burns - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H2 2019, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 4, 2, 17, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).

- The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Burns - Pipeline Review, H2 2019

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Burns - Overview
Burns - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Burns - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Burns - Companies Involved in Therapeutics Development
Aegle Therapeutics Corp
AlgiPharma AS
Alliance Pharma Plc
Amarantus Bioscience Holdings Inc
Anterogen Co Ltd
Bioharmony Therapeutics Inc
Biomendics LLC
CFM Pharma Holding BV
Destiny Pharma Plc
Energenesis Biomedical Co Ltd
FortuneRock (China) Ltd
GNT Pharma Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Hypo-Stream Ltd
Madam Therapeutics BV
Mallinckrodt Plc
MediWound Ltd
MicroCures Inc
NeoMatrix Therapeutics Inc
Novion Technologies Inc
Phagelux Inc
Riptide Bioscience Inc
Roji Ltd
Se-cure Pharmaceuticals Ltd
Shulov Innovative Science Ltd
Stemsynergy Therapeutics Inc
TGV-Inhalonix Inc
Theragnostic Technologies Inc
TreeFrog Therapeutics SAS
USV Pvt Ltd
viDA Therapeutics Inc
Washburn Therapeutics Inc
Burns - Drug Profiles
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGLE-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BH-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Burns and Bone Fractures - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bromelains - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Dermatology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENERGIF-711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epidermal growth factor biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neu-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligomer G for Burn Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-01SS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Activate FGFR for Cardiovascular, CNS, Dermatology and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrvinium pamoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize EPCR for Wounds and Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RNAi Gene therapy to Inhibit FL2 for Erectile Dysfunction, Burns and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAAP-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9X0125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silver sulfadiazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Burns and Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tolasure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vanadis-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTI-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XF-70 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burns - Dormant Projects
Burns - Discontinued Products
Burns - Product Development Milestones
Featured News & Press Releases
Oct 02, 2019: Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
Sep 24, 2019: Mallinckrodt reports positive burn treatment results
Sep 03, 2019: NexoBrid Highlighted in 39 presentations at the 18th European Burns Association Congress in Helsinki
Jun 04, 2019: NexoBrid receives Marketing Authorization from Peru's Ministry of Health
May 29, 2019: BARDA upsizes support for NexoBrid with an additional $21 million to fund continuous access treatment protocol for thermal burn
Apr 24, 2019: Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft Regenerative Skin Tissue in Madison, Wis.
Jan 23, 2019: MediWound reports positive top-line data from NexoBrid study
Oct 15, 2018: Mallinckrodts Stratatech company awarded $26 million in additional BARDA funding for pediatric studies of stratagraft skin tissue in thermal burns
Sep 24, 2018: MediWound awarded additional BARDA contract valued Up to $43 Million for development of NexoBrid for sulfur mustard injuries
Sep 05, 2018: NexoBrid receives marketing authorization from Russia's Ministry of Health
Jul 18, 2018: U.S. FDA designates Mallinckrodt's StrataGraft as regenerative medicine advanced therapy
Jun 19, 2018: MediWound Expands Its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.
Jun 11, 2018: MediWound Completes Enrollment in NexoBrid U.S. Phase 3 DETECT Study
Jun 04, 2018: NexoBrid Receives Marketing Authorization From South Koreas Ministry of Health
Apr 09, 2018: MediWound's NexoBrid to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Burns, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Universities/Institutes, H2 2019
Table 8: Number of Products by Stage and Target, H2 2019
Table 9: Number of Products by Stage and Mechanism of Action, H2 2019
Table 10: Number of Products by Stage and Route of Administration, H2 2019
Table 11: Number of Products by Stage and Molecule Type, H2 2019
Table 12: Burns - Pipeline by Aegle Therapeutics Corp, H2 2019
Table 13: Burns - Pipeline by AlgiPharma AS, H2 2019
Table 14: Burns - Pipeline by Alliance Pharma Plc, H2 2019
Table 15: Burns - Pipeline by Amarantus Bioscience Holdings Inc, H2 2019
Table 16: Burns - Pipeline by Anterogen Co Ltd, H2 2019
Table 17: Burns - Pipeline by Bioharmony Therapeutics Inc, H2 2019
Table 18: Burns - Pipeline by Biomendics LLC, H2 2019
Table 19: Burns - Pipeline by CFM Pharma Holding BV, H2 2019
Table 20: Burns - Pipeline by Destiny Pharma Plc, H2 2019
Table 21: Burns - Pipeline by Energenesis Biomedical Co Ltd, H2 2019
Table 22: Burns - Pipeline by FortuneRock (China) Ltd, H2 2019
Table 23: Burns - Pipeline by GNT Pharma Co Ltd, H2 2019
Table 24: Burns - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, H2 2019
Table 25: Burns - Pipeline by Hypo-Stream Ltd, H2 2019
Table 26: Burns - Pipeline by Madam Therapeutics BV, H2 2019
Table 27: Burns - Pipeline by Mallinckrodt Plc, H2 2019
Table 28: Burns - Pipeline by MediWound Ltd, H2 2019
Table 29: Burns - Pipeline by MicroCures Inc, H2 2019
Table 30: Burns - Pipeline by NeoMatrix Therapeutics Inc, H2 2019
Table 31: Burns - Pipeline by Novion Technologies Inc, H2 2019
Table 32: Burns - Pipeline by Phagelux Inc, H2 2019
Table 33: Burns - Pipeline by Riptide Bioscience Inc, H2 2019
Table 34: Burns - Pipeline by Roji Ltd, H2 2019
Table 35: Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H2 2019
Table 36: Burns - Pipeline by Shulov Innovative Science Ltd, H2 2019
Table 37: Burns - Pipeline by Stemsynergy Therapeutics Inc, H2 2019
Table 38: Burns - Pipeline by TGV-Inhalonix Inc, H2 2019
Table 39: Burns - Pipeline by Theragnostic Technologies Inc, H2 2019
Table 40: Burns - Pipeline by TreeFrog Therapeutics SAS, H2 2019
Table 41: Burns - Pipeline by USV Pvt Ltd, H2 2019
Table 42: Burns - Pipeline by viDA Therapeutics Inc, H2 2019
Table 43: Burns - Pipeline by Washburn Therapeutics Inc, H2 2019
Table 44: Burns - Dormant Projects, H2 2019
Table 45: Burns - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 46: Burns - Dormant Projects, H2 2019 (Contd..2), H2 2019
Table 47: Burns - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Burns, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Top 10 Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Top 10 Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019
  • Global Botox Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
    Published: 07-Jan-2020        Price: US 3480 Onwards        Pages: 108
    Summary Market Overview The global Botox market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 12.0% in the forecast period of 2020 to 2025 and will expected to reach USD 9424.1 million by 2025, from USD 5997.2 million in 2019. The Botox market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis,......
  • Global Pressure Ulcer Treatment Products Market Research Report 2020
    Published: 03-Jan-2020        Price: US 2900 Onwards        Pages: 97
    Pressure ulcer is an open wound on the skin. Pressure ulcer occurs due to the breakdown of skin and underlying tissues through excessive pressure on an area of the skin. Some of the symptoms of pressure ulcer are redness of the skin that worsens with time, and blisters on the area and then an open sore. Pressure ulcer commonly occur on the elbows, back of the head, buttocks, heels, shoulders, hips, ankles, and back. The classification of Pressure Ulcer Treatment Products includes Beds, Ma......
  • Global Hyaluronic Acid Dermal Filler Market Research Report 2020
    Published: 02-Jan-2020        Price: US 2900 Onwards        Pages: 99
    Hyaluronic Acid Dermal Filler are the product can be used to smooth away wrinkles and fine line, create fuller and more accentuated lips, and adding facial volume and contour. The global Hyaluronic Acid Dermal Filler market is valued at 589.4 million US$ in 2020 is expected to reach 1084.6 million US$ by the end of 2026, growing at a CAGR of 9.0% during 2021-2026. This report focuses on Hyaluronic Acid Dermal Filler volume and value at the global level, regional level and c......
  • Global Onychomycosis (Tinea Unguium) Drug Market Research Report 2020
    Published: 01-Jan-2020        Price: US 2900 Onwards        Pages: 95
    Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate. Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease. USA is the largest consumption place, with a consumption market share nearly 33.14% in 2016. Following USA, Europe is the second largest consumption place with the consumption market share of 23.66%.Market competition is intense. Johnson & Johnson, GSK,......
  • Global Dermal Filler Market Research Report 2020
    Published: 01-Jan-2020        Price: US 2900 Onwards        Pages: 123
    Dermal fillers help to diminish facial lines and restore volume and fullness in the face. Dermal fillers can be used to: plump thin lips, enhance shallow contours, soften facial creases and wrinkles and improve the appearance of recessed scars Dermal fillers can be very helpful in those with early signs of aging, or as a value-added part of facial rejuvenation surgery. In this report, HA = hyaluronic acid; CaHA = calcium hydroxylapatite; PLLA = poly-L-lacti......
  • Global Dermal Fillers Market Research Report 2020
    Published: 01-Jan-2020        Price: US 2900 Onwards        Pages: 122
    Dermal fillers help to diminish facial lines and restore volume and fullness in the face. Dermal fillers can be used to: plump thin lips, enhance shallow contours, soften facial creases and wrinkles and improve the appearance of recessed scars Dermal fillers can be very helpful in those with early signs of aging, or as a value-added part of facial rejuvenation surgery. Asia-Pacific is the largest consumption place, with a consumption market share nearly 39% in 20......
  • Global Dermatology Drug Market Professional Survey 2019 by Manufacturers, Regions, Types and Applications, Forecast to 2024
    Published: 30-Dec-2019        Price: US 2600 Onwards        Pages: 185
    In this report, we analyze the Dermatology Drug industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We also make a p......
  • Global Botox Market Growth 2019-2024
    Published: 30-Dec-2019        Price: US 3660 Onwards        Pages: 134
    According to this study, over the next five years the Botox market will register a 13.0% CAGR in terms of revenue, the global market size will reach US$ 8171.5 million by 2024, from US$ 5012.1 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Botox business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Botox market by product type, application, key m......
  • Global Acne Drugs Market Data Survey Report 2015-2025
    Published: 27-Dec-2019        Price: US 1500 Onwards        Pages: 66
    Summary The global Acne Drugs market will reach xxx Million USD in 2020 with CAGR xx% 2020-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers profile, products & services, sales data of business Global market size by Major End-Use Global market size by Major Type Key manufacturers are included based on company profile, sales da......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs